Infinity Pharma (INFI) Tops Q3 EPS by 47c

Infinity Pharma (NASDAQ: INFI) reported Q3 EPS of ($0.39), $0.47 better than the analyst estimate of ($0.86).

At September, 2016, Infinity had total cash, cash equivalents and available-for-sale securities of $112.3 million, compared to $146.4 million at June 30, 2016.

For earnings history and earnings-related data on Infinity Pharma (INFI) click here.

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• United Community Banks (UCBI) Tops Q1 EPS by 2c
• Capitol Federal Financial (CFFN) Misses Q2 EPS by 1c